{"DataElement":{"publicId":"2431598","version":"1","preferredName":"Gleason Histopathologic Grade Secondary Pattern Integer","preferredDefinition":"Second most predominant Gleason pattern present in an invasive prostate carcinoma.","longName":"2431390v1.0:2433968v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2431390","version":"1","preferredName":"Gleason Grade for Prostate Cancer Secondary Gleason Score For Prostate Cancer","preferredDefinition":"definition pending_definition pending","longName":"2431294v1.0:2431250v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2431294","version":"1","preferredName":"Gleason Grade for Prostate Cancer","preferredDefinition":"definition pending","longName":"C28107","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Grading System","conceptCode":"C28107","definition":"A grading system for prostatic carcinoma based on the microscopic glandular architectural patterns of the malignant epithelial cells. Nuclear atypia is not evaluated. It defines five patterns or grades which reflect decreasing differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05DCF477-9AD8-3BD3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-18","endDate":null,"createdBy":"UMLLOADER_CAP","dateCreated":"2005-11-18","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2431250","version":"1","preferredName":"Secondary Gleason Score For Prostate Cancer","preferredDefinition":"definition pending","longName":"C48604","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Secondary Gleason Pattern","conceptCode":"C48604","definition":"The second most prevalent Gleason pattern in a prostate biopsy or prostatectomy specimen. The Gleason score is defined by adding the most prevalent (primary) and second most prevalent (secondary) patterns.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05DCE808-3000-3574-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-18","endDate":null,"createdBy":"UMLLOADER_CAP","dateCreated":"2005-11-18","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2222502","version":"1","preferredName":"UML DEFAULT CD","preferredDefinition":"Default Conceptual Domain for UML Loader","longName":"UML DEFAULT CD","context":"caCORE","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5E53F3B-47A4-52D1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-04-29","modifiedBy":"DWARZEL","dateModified":"2021-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05DE0BB0-EAB6-44A1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-18","endDate":null,"createdBy":"UMLLOADER_CAP","dateCreated":"2005-11-18","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Permission to Release DEC granted by primary curator in 8/2008","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2433968","version":"1","preferredName":"Gleason Score for Prostate Cancer Integer","preferredDefinition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable._The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable._A number with no fractional part.","longName":"2433968v1.0","context":"NCIP","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","minLength":"1","maxLength":"1","minValue":"1","maxValue":"5","decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2183782","version":"1","preferredName":"NCIP","preferredDefinition":"Cancer Biomedical Informatics Grid","longName":"NCIP","context":"NCIP","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DACB2549-3BE3-73F7-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-05-19","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2434122","version":"1","preferredName":"Gleason Score Integer","preferredDefinition":"A system of grading prostate cancer cells to determine the best treatment and to predict how well a person is likely to do. A low Gleason score means the cancer cells are very similar to normal prostate cells; a high Gleason score means the cancer cells are very different from normal. :A number with no fractional part.","longName":"C28084:C45255","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score for Prostate Cancer","conceptCode":"C28084","definition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"06674CCB-D037-04A9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"CROWLEYR","dateCreated":"2005-11-28","modifiedBy":"ONEDATA","dateModified":"2005-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CAP PROTOCOLS:College of American Pathologists Cancer Protocols","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06674CCB-CEDA-04A9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"CROWLEYR","dateCreated":"2005-11-28","modifiedBy":"CURTIST","dateModified":"2010-09-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2534075","version":"1.2","longName":"caTISSUE CAE","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812224","version":"1","longName":"edu.pitt.cabig.cae.domain.prostate","context":"NCIP"}]},{"publicId":"2857187","version":"1","longName":"CAP Cancer Checklists","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812065","version":"1","longName":"edu.upmc.opi.cabig.caties.cap.domain.prostate","context":"NCIP"}]}],"AlternateNames":[{"name":"edu.pitt.cabig.cae.domain.prostate.GleasonHistologicGrade.secondaryPattern","type":"UML Qualified Attr","context":"NCIP"},{"name":"GleasonHistologicGrade:secondaryPattern","type":"UML Class:UML Attr","context":"NCIP"},{"name":"edu.upmc.opi.cabig.caties.cap.domain.prostate.GleasonHistopathologicGrade.secondaryPattern","type":"UML Qualified Attr","context":"NCIP"},{"name":"GleasonHistopathologicGrade:secondaryPattern","type":"UML Class:UML Attr","context":"NCIP"}],"ReferenceDocuments":[{"name":"Secondary Pattern","type":"Preferred Question Text","description":"Secondary Pattern","url":null,"context":"NCIP"}],"origin":"CAP PROTOCOLS:College of American Pathologists Cancer Protocols","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05DE6D61-A624-6165-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"UMLLOADER_CAP","dateCreated":"2005-11-18","modifiedBy":"REEVESD","dateModified":"2009-07-16","changeDescription":"Permission to Release CDE granted by primary curator, Linda Schmandt, in 8/2008","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}